Lycopene Took the Credit for the Tomato. In 2005 the FDA Made It Give the Credit Back.

The Oasis Health Journal · Submitted July 20, 2026 · 5:15 PM ET

In 1995, Harvard researchers combed through the diets of a large cohort of male health professionals and found something odd in the produce aisle. Out of 46 fruits and vegetables, three stood out: tomatoes, tomato sauce, and pizza. Pizza. A study got pizza onto a list of protective foods. That is the single greatest thing nutritional epidemiology has ever done for morale.

The authors noted those foods share a red pigment called lycopene, and that lycopene was the only carotenoid in the analysis tied to lower risk. Beta-carotene, alpha-carotene, lutein and beta-cryptoxanthin all sat there doing nothing.

The supplement industry read that sentence, put the paper down, and started filling capsules.

Then the FDA read the whole thing

In 2004 the agency received two petitions asking to put cancer-risk claims on tomato products and lycopene supplements. On November 8, 2005, it answered both.

The FDA found no credible evidence for an association between lycopene intake and reduced risk of prostate, lung, colorectal, gastric, breast, ovarian, endometrial, or pancreatic cancer. Not weak evidence. No credible evidence. The molecule went home with nothing.

What did get something was the tomato. The agency allowed one narrow claim for tomatoes and tomato sauce, and required the label to carry the sentence 'FDA concludes that there is little scientific evidence supporting this claim.' That is the most reluctant endorsement in the history of food labeling. It reads less like an approval and more like a hostage note.

The FDA's own reviewers published the full analysis in the Journal of the National Cancer Institute in 2007, in case anyone suspected the agency was being coy. It was not being coy. It just could not find the evidence.

So the credit went to the food, not the pigment. That distinction is the entire story. A tomato is not a lycopene capsule with skin on it. It also carries phytoene and phytofluene (two colorless carotenoids nobody puts on a label because they photograph badly), plus potassium, fiber, quercetin, naringenin and rutin. Pull one red molecule out of that and what you have is a red molecule.

Where lycopene actually has receipts

Here is the part that gets skipped, because it is quieter than a cancer headline. Lycopene has been building a real evidence file somewhere else entirely: blood pressure.

An umbrella review in Food and Function, first published in December 2025, went through nine systematic reviews on tomato-derived lycopene and cardiovascular risk. It kept only the five rated moderate to high quality, then pooled them. Systolic pressure came down about 2.41 mmHg. Diastolic came down about 1.33 mmHg. Both were graded high certainty under GRADE, with zero heterogeneity between reviews, which almost never happens in supplement research.

Two and a half points is not a dramatic number. It is also not zero. The authors point out that in the large drug trials, every 5 mmHg drop in systolic pressure tracks with roughly 10 percent fewer major cardiovascular events. The dose that produced it was 5 to 30 mg a day, which the reviewers translate to about one to two raw tomatoes.

An earlier meta-analysis of 10 randomized trials in 688 people found the same direction, with bigger effects in people who started with higher pressure, took at least 15 mg, and stayed on it at least eight weeks.

The cholesterol results, meanwhile, were a mess. Total cholesterol, LDL, triglycerides and HDL all came back non-significant in the pooled analysis, and HDL was graded very low certainty because the reviews could not agree with each other at all. If someone is selling you lycopene for cholesterol, they are running ahead of the data.

One more file, opened in 2025

A systematic review and meta-analysis in the International Journal of Molecular Sciences, published July 2025, looked at lycopene and male reproductive markers. Four clinical studies. 151 participants. Small.

Sperm concentration improved (standardized mean difference 0.33, p = 0.037), with no heterogeneity across the studies. Nonprogressive motility improved as well (0.45, p = 0.032). Total motility got close and missed (p = 0.083). Morphology, semen volume and DNA damage did not move.

The honest read: two modest, consistent signals pulled from a very small pile of trials, and the motility finding rests on only two of them. The authors say larger high-quality randomized trials are needed before anyone recommends this. They are right. This is an open file, not a closed one.

The absorption detail nobody mentions

Lycopene in a raw tomato is mostly all-trans, and all-trans is poorly absorbed. Heat flips it into cis isomers, which slip into mixed micelles more willingly and clump together less.

In a human trial published in the British Journal of Nutrition, a cis-rich tomato sauce produced a lycopene response of 7.30 nmol x h/l versus 4.74 for an all-trans-rich sauce. The catch is that the all-trans sauce actually contained more lycopene per 100 grams. Less pigment, more absorbed. Fresh tomatoes and unheated juice are the poorer sources here, which is the opposite of what raw-food logic predicts.

Which means the Italian grandmother simmering sauce in olive oil for three hours was running a bioavailability protocol. She just never published.

What to do with it

Eat cooked tomatoes with some fat. That part is free and it works.

If you take it in a bottle, you will usually find lycopene riding along inside a prostate formula next to saw palmetto and beta-sitosterol, or tucked into a broad-spectrum multivitamin. Standalone lycopene exists too. Take it with a meal containing fat, because a fat-soluble carotenoid swallowed with plain water is largely a donation to your plumbing.

One note on how we handle it. Carotenoids oxidize, and lycopene in particular does not enjoy a year in a warm warehouse. We source professional-grade formulas fresh per order rather than sitting on aging inventory, so your box takes a few extra days to arrive. The tradeoff is potency you can count on. Slower shipping, stronger contents.

This article is for education only. It is not medical advice, diagnosis, or treatment, and nothing here is intended to prevent or treat any disease. Talk with your clinician before starting a supplement, especially if you take blood pressure medication.

Sources

1. Giovannucci E, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst, 1995
2. U.S. FDA. Qualified Health Claims: Letters of Enforcement Discretion (tomato and lycopene petitions, November 8, 2005)
3. Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. FDA's Evidence-Based Review for Qualified Health Claims: Tomatoes, Lycopene, and Cancer. J Natl Cancer Inst, 2007
4. Nam YE, Hwang IG, Jang HH. Role of lycopene from tomato on cardiovascular risk: an umbrella review of systematic reviews and meta-analyses. Food & Function, 2025
5. Association of Lycopene and Male Reproductive Health: Systematic Review and Meta-Analysis. Int J Mol Sci, 2025
6. Unlu NZ, et al. Lycopene from heat-induced cis-isomer-rich tomato sauce is more bioavailable than from all-trans-rich tomato sauce in human subjects. Br J Nutr, 2007
7. Rezaei Kelishadi M, et al. Lycopene supplementation and blood pressure: systematic review and meta-analyses of randomized trials. J Herb Med, 2022